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Abstract We describe a 62-year-old female diagnosed
with Alzheimer’s disease, who had been treated with
donepezil for approximately 1 year. When she developed
a low-grade fever and digestive complaints, her family
physician interpreted these symptoms as side effects of the
drug and ordered donepezil to be discontinued. Not only
was there no improvement of the somatic symptoms after
discontinuation of donepezil, but there was also a wors-
ening of the dementia symptoms, culminating in delirium.
When donepezil was re-prescribed, the delirium resolved
and the patient’s mental state stabilized. The authors urge
great caution in discontinuing treatment with acetylcho-
linesterase inhibitors such as donepezil.
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Introduction
Donepezil is a selective inhibitor of acetylcholinesterase,
used in the treatment of Alzheimer’s disease (AD). The
administration of acetylcholinesterase inhibitors (IAchEs)
should be systematic and long term. However, for numer-
ous reasons IAchEs are often abruptly terminated. The
causes of this most often include the occurrence of side
effects, lack of efficacy, or sometimes caregiver error or
negligence [1]. Terminating treatment, especially abruptly,
is not without consequences for the patient. It has been
reported that intense hallucinations can occur after sudden
donepezil withdrawal [2]. One published study has sug-
gested that discontinuation of treatment with donepezil
may bring withdrawal symptoms [3]. Attempts have also
been made to use donepezil to reduce delirium in patients
with dementia [4–6]. There has also been a reported case of
a patient who became delirious 3 days after he had begun
to take donepezil [7].
Below we present a clinical case from our own practice,
describing a patient who had been treated with donepezil
for several months, while the sudden termination of the
drug caused delirium.
Case report
This 62-year-old woman was first seen by a psychiatrist in
2007. About 10 months before this consultation, the family
physician had diagnosed her with mild dementia. An MRI
examination revealed generalized cortical degeneration,
especially in the medial temporal lobes. The patient’s
MMSE score was 21 points, and her ADAS-cog score was
22 points. Standard laboratory tests revealed no clinically
significant abnormalities. Alzheimer’s disease was diag-
nosed, and donepezil (in generic form) was prescribed, at a
dosage of 5 mg daily. As the drug was tolerated so well by
the patient, after 6 weeks the dosage was increased to
10 mg once a day.
The patient took donepezil systematically until August
2008. During that period she was taking no other drugs,
except for a few cold remedies (paracetamol, aspirin). She
reported for regular checkups with her caregiver (her
husband) once every 4 weeks on average. Her mental state
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was found to be stable. No significant abnormalities were
found in laboratory tests or EKG examination.
In August 2008, the patient had symptoms of a somatic
disease. Due to difficult communication with the patient,
the only complaints that could be confirmed were head-
aches and stomachaches. She had no appetite. Her tem-
perature went up to 37.8C, and the heart rate was 90.
There were slight electrolyte changes: 104 mmol/l Cl,
4.0 mmol/l K, 147 mmol/l Na. There were no clinically
significant changes in urine culture and hematology, apart
from mild increase in some parameters of white cell count
(total WBC and neutrophils). Based on the digestive
symptoms (aches, loss of appetite), the family physician
decided that the symptoms were probably a side effect of
donepezil treatment and recommended termination of
treatment. For the next 24 h, the patient did not improve:
she remained bedridden, and her temperature was still
37.7C.
Within 3 days after the medicine had been withdrawn,
the caregiver asked for psychiatric consultation due to
significantly intensified dementia symptoms and increased
anxiety. During the consultation, the patient showed a
fluctuating level of consciousness and was unable to pay
full attention; her behavior also demonstrated possible
hallucinations. An attempt to conduct a neuropsychological
assessment failed because of her fluctuating level of con-
sciousness. The patient had also not slept the previous two
nights, which increased her anxiety. Delirium was diag-
nosed, together with a somatic infection, on the basis of
prior morphological tests and the clinical state. It was
decided that donepezil should be reintroduced in the pre-
vious dosage of 10 mg, but divided into 2 9 5 mg. Anti-
inflammatory treatment was also prescribed: aspirin
(1,500 mg) and ascorbic acid. EKG and X-ray examina-
tions were also recommended.
Two days later, the patient was consulted again at home.
Her behavior was calm, it was possible to cooperate with
her, and there were no signs that would indicate the pres-
ence of psychotic symptoms. She still showed a loss of
appetite and stayed in bed most of the time. The EKG and
X-ray examinations had not revealed any pathological
changes. Her temperature was 36.8C, and her pulse was
82. According to the patient’s husband, she had calmed
down significantly the next day after taking donepezil and
had slept from early morning.
Five days after renewing donepezil treatment, her hus-
band called to inform that the patient had regained her
appetite and was no longer bedridden; her temperature was
normal. A subsequent consultation in the outpatient clinic
took place 7 days later (14 days after the delirium). The
patient did not display a fluctuating level of consciousness;
she was disoriented in time, but not in space, and was able
to concentrate. However, once in every few hours, she
demonstrated increased agitation and intensified disorien-
tation. These episodes lasted from several minutes to about
an hour. According to her husband, the patient wanted to
leave home at these times and displayed great anxiety.
Verbal persuasion was sufficient to keep her at home and
calm her down after some time. Her MMSE score was now
17, and the ADAS-cog score was 34. No significant
abnormalities were found in laboratory tests. The former
dosage of donepezil was reintroduced (10 mg in one dose).
During subsequent monthly consultations, no disorders
of consciousness were observed. Short-lasting episodes of
agitation and intensified disorientation lasted for 10 days
after reintroducing donepezil and then receded.
A complete follow-up examination, including neuro-
psychological assessment, was done within 6 months after
the delirium episode. This examination confirmed intensi-
fication of cognitive deficiency, which was revealed a week
after the delirium, but without any features of further
progression in the following months.
Discussion
Delirium is very common in many geriatric diseases. It is
often not diagnosed, and is frequently connected with
unfavorable prognosis [8]. The occurrence of delirium is
dependent on a number of factors. Dementive disorders
make the occurrence of delirium more probable [9].
Delirium seems to have an influence on the further pro-
gression of dementia [10].
Greater importance is ascribed to acetylcholine than to
the other cerebral neurotransmitters in the pathogenesis of
delirium. It has been proved that there is a connection
between delirium and numerous substances that influence
the level of acetylcholine in the reticular formation [11].
A relation has also been noticed between the intensity of
delirium symptoms and the concentration of anticholiner-
gic substances [12].
In the described case, there is a visible temporal con-
nection between withdrawing donepezil and the occurrence
of delirium. However, several factors occurred at one time,
including an infection, which caused an increase in tem-
perature and immobilization. The loss of appetite prompted
an increased intake of fluids, which was indicated by dis-
crete electrolytic abnormalities. All these factors are con-
sidered to be risk factors for delirium [13]. Nevertheless,
the rapid improvement of our patient’s mental state after
administering donepezil again, despite lingering somatic
symptoms, proves its key role in the etiology of delirium in
this case. The improvement occurred within just a few
hours after the medicine had been taken, which may
be connected with the fact that peak plasma levels of
donepezil are reached in 3–4 h. On the other hand, the
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transient states of agitation and intensified disorientation
that appeared within several days after the delirium, could
be connected with steady-state concentration, which is
achieved within 15–21 days [14]. Clinical symptoms in our
patient manifested markedly earlier than in cases described
by Singh and Dudley [3]. This difference probably results
from the influence of additional factors in our patient,
namely infection and the fact that she was not administered
other psychotropic agents [3].
This case illustrates the necessity of maintaining
extreme caution when making the decision to terminate
treatment with chronically administrated drugs in demen-
tia, particularly in the presence of other potential risk
factors for delirium.
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